Methocarbamol API Manufacturers & Suppliers
14 verified resultsCommercial-scale Suppliers
All certificates
All certificates
All certificates
All certificates
All certificates
All certificates

All certificates
All certificates
All certificates
All certificates
All certificates
All certificates

All certificates
All certificates






Methocarbamol | CAS No: 532-03-6 | GMP-certified suppliers
A medication that provides short‑term relief of discomfort associated with acute, painful musculoskeletal conditions, supporting muscle spasm management for clinical and consumer markets.
Therapeutic categories
Primary indications
- Methocarbamol tablets and intramuscular injections are indicated in the United States as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions
- [Label,L6268] Oral methocarbamol in America may be given up to 1500mg 4 times daily for 2-3 days
- In Canada, methocarbamol containing oral formulations are sold over the counter for pain associated with muscle spasm
Product Snapshot
- Methocarbamol is available as an oral small‑molecule formulation and as injectable solutions for intramuscular or intravenous use
- It is used as an adjunct for relief of discomfort associated with acute, painful musculoskeletal conditions and for muscle spasm–related pain
- It is approved in the United States and Canada, with human and veterinary approvals in these markets
Clinical Overview
Methocarbamol exhibits pharmacodynamic effects consistent with central nervous system depression. Although its mechanism is not fully defined, available data indicate inhibition of spinal polysynaptic reflexes and reduced nerve transmission within spinal and supraspinal pathways. It also prolongs the refractory period of muscle cells but does not directly affect muscle fiber contraction or peripheral neuromuscular transmission. In animal studies, it has shown anticonvulsant properties following electric shock.
Absorption, distribution, metabolism, and excretion characteristics are reported in the literature, but detailed quantitative parameters vary and are formulation dependent. The drug is generally considered to have a rapid onset of action with hepatic metabolism and renal elimination of metabolites.
Safety considerations include dose‑related central nervous system depression, with potential for drowsiness, dizziness, and impaired coordination. Caution is warranted in combination with other CNS depressants. Intramuscular or intravenous administration does not confer local anesthetic activity. Use in specific populations, including those with hepatic impairment and older adults, requires clinical judgment due to altered pharmacokinetic handling or increased sensitivity.
Brand and combination products vary by region, with long‑standing clinical use in musculoskeletal care settings.
For API procurement, suppliers should provide evidence of compliance with pharmacopoeial specifications, validated impurity controls, and stable manufacturing processes to support consistent quality across global regulatory environments.
Identification & chemistry
| Generic name | Methocarbamol |
|---|---|
| Molecule type | Small molecule |
| CAS | 532-03-6 |
| UNII | 125OD7737X |
| DrugBank ID | DB00423 |
Pharmacology
| Summary | Methocarbamol is a centrally acting skeletal muscle relaxant thought to exert its effect through general CNS depressant activity. It reduces spinal and supraspinal polysynaptic reflex transmission and may prolong the refractory period of muscle cells without directly affecting muscle fibers or neuromuscular transmission. The drug has been associated with carbonic anhydrase 1 as a molecular target, though its therapeutic relevance remains unclear. |
|---|---|
| Mechanism of action | The mechanism of action of methocarbamol is thought to be dependant on its central nervous system depressant activity.This action may be mediated through blocking spinal polysynaptic reflexes, decreasing nerve transmission in spinal and supraspinal polysynaptic pathways, and prolonging the refractory period of muscle cells.Methocarbamol has been found to have no effect on contraction of muscle fibres, motor end plates, or nerve fibres. |
| Pharmacodynamics | Methacarbamol is a skeletal muscle relaxant with an unknown mechanism of action.Methacarbamol has been shown to block spinal polysynaptic reflexes, decrease nerve transmission in spinal and supraspinal polysynaptic pathways, and prolong the refractory period of muscle cells.Methocarbamol does not act as a local anesthetic upon injection.In animal studies, methocarbamol also prevents convulsions after electric shock. |
Targets
| Target | Organism | Actions |
|---|---|---|
| Carbonic anhydrase 1 | Humans | inhibitor |
ADME / PK
| Absorption | The time to maximum concentration is 1.1 hours for both healthy patients and those on hemodialysis.The maximum plasma concentration is 21.3mg/L for healthy patients and 28.7mg/L in hemodialysis patients.The area under the curve for healthy patients is 52.5mg/L\*hr and 87.1mg/L*hr in hemodialysis patients.AUC% based on terminal elimination half life is 2% for healthy patients and 4% for hemodialysis patients. Older studies report maximum plasma concentrations in 0.5 hours. |
|---|---|
| Half-life | The elimination half life is 1.14 hours in healthy subjects and 1.24 hours in subjects with renal insufficiency.Older studies report half lives of 1.6-2.15 hours. |
| Protein binding | Methocarbamol is 46-50% protein bound in healthy patients and 47.3-48.9% protein bound in hemodialysis patients. |
| Metabolism | Methocarbamol is metabolized in the liver by demethylation to 3-(2-hydroxyphenoxy)-1,2-propanediol-1-carbamate or hydroxylation to 3-(4-hydroxy-2-methoxyphenoxy)-1,2-propanediol-1-carbamate.Methocarbamol and its metabolites are conjugated through glucuronidation or sulfation. |
| Route of elimination | In humans the majority of the dose is eliminated in the urine.In dogs, 88.85% of the dose is eliminated in urine and 2.14% in the feces.In rats, 84.5-92.5% of the dose is eliminated in the urine and 0-13.3% is eliminated in the feces. |
| Volume of distribution | Volume of distribution data in humans is scarce. In horses, the volume of distribution is 515-942mL/kg at steady state or 724-1130mL/kg. |
| Clearance | 0.2-0.8L/h/kg. |
Formulation & handling
- Oral formulations are feasible due to good aqueous solubility and food-independent absorption, allowing straightforward tablet or capsule design.
- Parenteral products require attention to solution stability and pH control to maintain solubility and prevent precipitation during IV/IM administration.
- As a small-molecule solid with moderate hydrophilicity (logP ~0.45), it handles well in standard solid-dose manufacturing with minimal need for solubilizers.
Regulatory status
| Lifecycle | The API is marketed in Canada and the US, where patent expiry timing indicates a late‑stage lifecycle with established market competition. These factors suggest a mature market environment with limited remaining exclusivity. |
|---|
| Markets | Canada, US |
|---|
Supply Chain
| Supply chain summary | Methocarbamol is an established, off‑patent product with no active originator presence in the current supply data, and its market is dominated by numerous generic manufacturers and repackagers. Branded and combination products are available mainly in the US and Canada, reflecting mature global distribution. Patent expiry long ago supports the broad, ongoing generic competition seen across the supply chain. |
|---|
Safety
| Toxicity | Overdose of methocarbamol may be associated with alcohol and other central nervous system depressants.[Label] Patients may experience nausea, drowsiness, blurred vision, hypotension, seizures, and coma.[Label] Treatment of overdose is generally through airway maintenance, monitoring urinary output, vital signs, and giving fluid intravenously if necessary.[Label] The oral LD50 in rats is 3576.2mg/kg. The FDA has classified methocarbamol as pregnancy category C.[Label] Animal and human studies have not been performed to determine the risks to a fetus, however fetal and congenital abnormalities have been reported.[Label] Methocarbamol is excreted in the milk of dogs, however it is unknown if this is also the case for humans.[Label] Caution should be exercised when taking methocarbamol while breastfeeding.[Label] Studies to assess the carcinogenicity, mutagenicity, or effects on fertility of methocarbamol have not been performed.[Label] |
|---|
- CNS‑depressant toxicity is potentiated by co‑exposure to alcohol or other sedatives
- Overdose manifestations include severe neurologic and cardiovascular depression (e
- G
Methocarbamol is a type of Muscle relaxants
Muscle relaxants are a subcategory of pharmaceutical active pharmaceutical ingredients (APIs) commonly used to alleviate muscle spasms and promote muscle relaxation. These medications act on the central nervous system (CNS) or directly on muscle fibers to reduce muscle tone and tension.
Muscle relaxants can be classified into two main groups: spasmolytics and neuromuscular blockers. Spasmolytics primarily target the CNS to inhibit the transmission of nerve signals, thus reducing muscle spasms. They are often prescribed for conditions such as back pain, muscle strains, and spasms caused by neurological disorders.
Neuromuscular blockers, on the other hand, act at the neuromuscular junction to prevent the transmission of nerve impulses, resulting in temporary paralysis of skeletal muscles. These medications are primarily used during surgical procedures to induce muscle relaxation and facilitate intubation.
Commonly prescribed muscle relaxants include benzodiazepines, such as diazepam and lorazepam, which have sedative properties and can provide relief from muscle spasms. Another class of muscle relaxants is the centrally acting skeletal muscle relaxants, including carisoprodol and cyclobenzaprine, which work by affecting neurotransmitters in the CNS.
It is important to note that muscle relaxants can cause side effects such as drowsiness, dizziness, and impaired coordination. They should only be used under the guidance of a healthcare professional, and the dosage and duration of treatment should be strictly followed to avoid dependence or other complications.
In conclusion, muscle relaxants are pharmaceutical APIs used to alleviate muscle spasms and promote muscle relaxation. They are available in different forms and can target the CNS or directly act on muscle fibers. It is crucial to consult a healthcare professional for proper diagnosis, prescription, and monitoring when using muscle relaxants.
Methocarbamol (Muscle relaxants), classified under Skeletal muscle relaxants
Skeletal muscle relaxants are a category of pharmaceutical active pharmaceutical ingredients (APIs) that are commonly used in the treatment of musculoskeletal conditions characterized by muscle spasms, stiffness, or tension. These medications work by targeting the central nervous system to reduce muscle activity and promote relaxation.
Skeletal muscle relaxants act on various receptors in the central nervous system, such as gamma-aminobutyric acid (GABA) receptors, to inhibit the transmission of nerve impulses and decrease muscle tone. This results in a reduction in muscle spasms, pain relief, and improved mobility.
There are different classes of skeletal muscle relaxants, including benzodiazepines, antispasmodics, and centrally acting muscle relaxants. Benzodiazepines, such as diazepam and lorazepam, exert their muscle relaxant effects by enhancing the activity of GABA receptors. Antispasmodics like cyclobenzaprine work by inhibiting the release of certain neurotransmitters involved in muscle contractions. Centrally acting muscle relaxants, such as baclofen and tizanidine, directly target the spinal cord to reduce muscle hyperactivity.
Skeletal muscle relaxants are commonly prescribed for conditions like muscle spasms, back pain, fibromyalgia, and multiple sclerosis. However, they are typically used for short-term treatment due to their potential side effects, including drowsiness, dizziness, and sedation.
It is important to note that skeletal muscle relaxants should only be used under the supervision and prescription of a qualified healthcare professional. Proper dosage and duration of treatment should be determined based on the patient's condition and medical history to ensure safe and effective use of these medications.
Methocarbamol API manufacturers & distributors
Compare qualified Methocarbamol API suppliers worldwide. We currently have 14 companies offering Methocarbamol API, with manufacturing taking place in 5 different countries. Use the table below to review supplier type, countries of origin, certifications, product portfolio and GMP audit availability.
| Supplier | Type | Country | Product origin | Certifications | Portfolio |
|---|---|---|---|---|---|
| Aarambh Life Science | Producer | India | India | CoA, GMP | 19 products |
| Boehringer Ingelheim | Producer | Germany | Unknown | CoA, USDMF | 35 products |
| Hänseler AG | Distributor | Switzerland | India | CoA, GMP | 174 products |
| LGM Pharma | Distributor | United States | World | BSE/TSE, CEP, CoA, GMP, MSDS, USDMF | 441 products |
| Pharm Rx Chemical Corp | Distributor | United States | China | BSE/TSE, CoA, GMP, MSDS, USDMF | 166 products |
| Seven Star Pharma | Producer | Taiwan | Taiwan | CoA, USDMF | 3 products |
| Shaoxing Hantai Pharma | Distributor | China | China | CoA | 162 products |
| Sinoway industrial Co.,Lt... | Distributor | China | China | CoA, GMP, ISO9001, USDMF | 757 products |
| Suzhou Lixin Pharmaceutic... | Producer | China | China | BSE/TSE, CoA, GMP, MSDS | 34 products |
| Synthokem Labs | Producer | India | India | CoA, EDMF/ASMF, ISO9001, KDMF, USDMF, WC | 9 products |
| Tenatra Exports Private L... | Distributor | India | India | BSE/TSE, CoA, FDA, GMP, MSDS | 263 products |
| Unnati Pharmaceuticals Pv... | Distributor | India | India | CoA | 70 products |
| Zhejiang Apeloa Tospo-Jia... | Producer | China | China | CoA, USDMF | 15 products |
| Zhejiang Haizhou | Producer | China | China | CoA, USDMF | 3 products |
When sending a request, specify which Methocarbamol API quality you need: for example EP (Ph. Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.).
Use the list above to find high-quality Methocarbamol API suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our help page to learn more about sourcing APIs via Pharmaoffer.
